Need Assistance?

US & Canada:
+
UK: +

FAQs

Resources

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Application Area

Carbetocin

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Carbetocin is a potent agonist of the oxytocin receptor, with improved in vivo stability over oxytocin.

Category

Peptide Inhibitors

Catalog number

BAT-010026

CAS number

37025-55-1

Molecular Formula

C45H69N11O12S

Molecular Weight

988.16

Size	Price	Stock	Quantity
10 mg	$199	In stock

Specification
Reference Reading

IUPAC Name

(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]-1-[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-[(4-methoxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]pyrrolidine-2-carboxamide

Synonyms

Duratocin; Pabal; Lonactene

Appearance

White to beige Powder

Purity

>98%

Density

1.218 g/cm3

Boiling Point

1477.9°Cat 760 mmHg

Sequence

Butyryl-Y(Me)IQNCPLG

Storage

Store at -20°C

InChI

InChI=1S/C45H69N11O12S.C2H4O2/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59;1-2(3)4/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64);1H3,(H,3,4)/t25-,28-,29-,30-,31-,32-,33-,38-;/m0./s1

InChI Key

AWSBRHKQUFVWPU-AJDWMHSWSA-N

Canonical SMILES

CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSCCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.CC(=O)O

1.Carbetocin compared to oxytocin in emergency cesarean section: a randomized trial.

Razali N1, Md Latar IL2, Chan YK3, Omar SZ2, Tan PC2. Eur J Obstet Gynecol Reprod Biol. 2016 Mar;198:35-9. doi: 10.1016/j.ejogrb.2015.12.017. Epub 2015 Dec 30.

OBJECTIVE: To evaluate the uterotonic effect of carbetocin compared with oxytocin in emergency cesarean delivery.

2.Carbetocin versus oxytocin in the management of atonic post partum haemorrhage (PPH) after vaginal delivery: a randomised controlled trial.

Maged AM1, Hassan AM2, Shehata NA3. Arch Gynecol Obstet. 2016 May;293(5):993-9. doi: 10.1007/s00404-015-3911-y. Epub 2015 Oct 28.

OBJECTIVE: The objective of this study is to compare the effectiveness and safety of carbetocin vs. oxytocin in the management of atonic post partum haemorrhage (PPH) after vaginal delivery.

3.In Vitro Comparative Effect of Carbetocin and Oxytocin in Pregnant Human Myometrium with and without Oxytocin Pretreatment.

Cole NM1, Carvalho JC, Erik-Soussi M, Ramachandran N, Balki M. Anesthesiology. 2016 Feb;124(2):378-86. doi: 10.1097/ALN.0000000000000940.

BACKGROUND: The purpose of this study was to compare in vitro contractile effects of oxytocin and carbetocin on human term pregnant myometrium with and without oxytocin pretreatment.

4.[Evaluation of efficacy and safety of pelvic arterial embolization in women with primary postpartum hemorrhage].

Tang PP1, Hu HY, Gao JS, Hu J, Zhong YF, Wang T, Song YN, Zhou XY, Yang JQ, Liu JT, Pan J, Shi HF. Zhonghua Fu Chan Ke Za Zhi. 2016 Feb 25;51(2):81-6. doi: 10.3760/cma.j.issn.0529-567X.2016.02.001.

OBJECTIVE: To evaluate the efficacy and safety of pelvic arterial embolization (PAE) in women with intractable primary postpartum hemorrhage (PPH).